At the center of the debate are the growing number of manufacturer demands for claims data as a condition of 340B pricing.
|Articles|April 5, 2004
White House targets Rx abuse in antidrug plan
Alarmed by the ease with which consumers can obtain controlled substances with impunity, the Bush Administration announces a new campaign against rogue pharmacies
Advertisement
Advertisement
Related to this article
Nicholas Rebold, PharmD, MPH, BCIDP, AAHIVP, discusses his team’s and patients’ experiences in a pharmacist-led antiretroviral initiative.
Zaid Fadul, MD, FS, FAAFP, introduces the Nolla Derm app, what it might mean for pharmacists and their patients, and where AI prescribing is headed in the future.
Among a collection of patients across 15 pharmacies, researchers assessed acceptability and satisfaction with pharmacist-led clinical services.
From expert sources and recent data updates to a look at cases amid the ongoing respiratory virus season, this is an updated look at 2026 measles outbreaks in the US.
Zaid Fadul, MD, FS, FAAFP, joins for part 2 to discuss what greater adoption of AI across health care ecosystems might mean for pharmacists, patients, and more.
For pharmacies competing with CVS and relying on Caremark to serve patients, the prospect of those businesses operating under separate ownership is significant.
Erin Albert of Mark Cuban Cost Plus Drugs explains how the Team Cuban Card offers transparent pricing and fair pay for independent pharmacies.
Advertisement
Advertisement